Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Efavirenz · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Efavirenz | DRUG | - |
| Stavudine | DRUG | - |
| Didanosine | DRUG | - |
| Lamivudine | DRUG | - |
Inclusion Criteria Patients must have: * Documented HIV infection with plasma HIV-RNA greater than or equal to 10,000 copies/ml. * A life expectancy of at least 12 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Current bilat...
Top 20 of 28 competitors
Efavirenz is a small molecule drug being studied for the treatment of HIV infections. It is currently in Phase 2 clinical development, with studies conducted in the United States involving patients aged 13 years and older.
Efavirenz is being developed by Merck & Company, Inc., which is publicly traded under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with HIV infections.
Efavirenz is in Phase 2 clinical development. Two Phase 2 studies have been completed, with a total of 120 participants enrolled. The drug is investigational and has not yet been approved for commercial use.
Efavirenz has been studied in two completed Phase 2 clinical trials: NCT00002225, which evaluated efavirenz in combination with stavudine and didanosine, and NCT00002227, which studied efavirenz in HIV-infected patients who had never taken anti-HIV drugs. Each trial enrolled 60 participants.
Efavirenz is also known by the brand name Sustiva, which is a common alternative name for the drug. It is being developed by Merck & Company, Inc. for the treatment of HIV infections.